WALTHAM

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Retrieved on: 
Tuesday, April 16, 2024
Sale, Prospectus, Cancer, Morgan Stanley, Vanderbilt Avenue, Security (finance), Form, TD Securities, Varick Street, Patient, 2nd Floor, S-3, TCR, Attention, Therapy, Telephone, Needham & Company

All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan.

Key Points: 
  • All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan.
  • TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering.
  • Morgan Stanley and TD Cowen are acting as joint book-running managers for the offering.
  • LifeSci Capital is acting as Lead Manager, and BTIG, H.C. Wainwright & Co. and Needham & Company are each acting as co-managers for the offering.

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Retrieved on: 
Tuesday, April 16, 2024
Patient, Cancer, T-ALL, MRD, HLA, Collection, Trial of the century, HCT, AML, IND, Blood, Syndrome, Acute myeloid leukemia, Acute leukemia, Neoplasm, TCR, Therapy, MDS, ALL, Medical imaging

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today provided an update on its solid tumor and heme malignancies clinical programs.

Key Points: 
  • “We continue to make meaningful progress across both our solid tumor and heme malignancies Phase 1 clinical programs.
  • This should allow for rapid enrollment into the treatment protocol over the course of the year,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
  • Phase 1 solid tumor clinical study has been initiated; first three patients expected to be dosed in early May 2024.
  • Completion of Phase 1 enrollment and reporting of one-year clinical and translational data on initial patients is anticipated in the second half of 2024.

Nano Dimension Refreshes Corporate Governance by Appointing Major General (Ret.) Eitan Ben-Eliahu to the Company’s Board of Directors

Retrieved on: 
Tuesday, April 16, 2024
RET, Aeronautics, Law, Bar-Ilan University, IAF, Tel Aviv Stock Exchange, Policy, Squadron, Yom Kippur War, 3D, 3D printing, Commander, Tel Aviv University, Television, AMP, Electronics, Advanced Management Program, Ethics, Open University, Harvard University, Major general, Management

Waltham, Mass, April 16, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printing solutions, today announced that Major General (Ret.) Eitan Ben-Eliahu is joining its Board of Directors (the “Board”).

Key Points: 
  • Eitan Ben-Eliahu is joining its Board of Directors (the “Board”).
  • During his long business career until his current appointments, Major General (Ret.)
  • Simon Fried, a co-founder of Nano Dimension, will step down from his position as a director after over 10 years with the Company.
  • Dr. Yoav Nissan-Cohen, Chairman, and Yoav Stern, CEO and member of the Board, of Nano Dimension issued a joint statement: “We are honored to add Major General (Ret.)

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 15, 2024
Sale, Idiopathic pulmonary fibrosis, Weill Cornell Medicine, University, Internal, Research and development, Epithelium, Investment, Fibroblast, Interstitial, Pleural effusion, IPF, LPE, Intensive care medicine, Administration, University of Giessen, University of Alabama, Patient, Acquisition, Fibrosis, Associate, Series, Therapy, G&A, Critical Care Medicine (journal), ALRN, Pharmaceutical industry

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Retrieved on: 
Monday, April 15, 2024
Momentum, Vaccination, CMS, Risk, Safety, SARS-CoV-2, Food, Health care, Pre-exposure prophylaxis, Patient, COVID-19, Immunodeficiency, Medicare, Interim, HCPCS, Pharmaceutical industry

In addition, CMS issued a product specific M code (M0224) covering the administration of PEMGARDA.

Key Points: 
  • In addition, CMS issued a product specific M code (M0224) covering the administration of PEMGARDA.
  • Both HCPCS codes are effective retroactively to March 22, 2024, the date of emergency use authorization (EUA) for PEMGARDA.
  • HCPCS is a group of standardized codes that represent medical procedures, supplies, products, and services.
  • For additional information about PEMGARDA, please see the full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.

Invivyd Announces CEO Transition

Retrieved on: 
Friday, April 12, 2024
COVID, Virology, Pre-exposure prophylaxis, Caregiver, Interim, COVID-19, Growth

WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effective immediately, while the Board institutes a search for a permanent CEO.

Key Points: 
  • WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effective immediately, while the Board institutes a search for a permanent CEO.
  • “The Invivyd Board of Directors is positioning the company for its next phase of growth,” said Marc Elia, Chairperson.
  • “Invivyd is poised to lead a brand-new paradigm in delivering novel, impactful monoclonal antibody (mAb) therapies for the pre-exposure prophylaxis (PrEP) of COVID-19, and we wish to fully unlock this capability and associated value creation.
  • Invivyd has tremendous potential to reach and support vulnerable populations and their caregivers with PEMGARDA and beyond,” said Mr. Gowler.

Benchmark at Rye Executive Director Receives Annual "President's Award"

Retrieved on: 
Monday, April 15, 2024
Bed, Caregiver, Barash, Rye, Amnesia, RYE, Dementia

RYE, N.H., April 15, 2024 /PRNewswire-PRWeb/ -- Benchmark, the largest senior living provider in New England, today announced that Nick Barash of Andover, Mass., executive director of Benchmark at Rye, a Mind & Memory Care community, has received the Benchmark 2023 President's Award, which is the Waltham-based company's highest honor for associates in a senior leadership role.

Key Points: 
  • RYE, N.H., April 15, 2024 /PRNewswire-PRWeb/ -- Benchmark , the largest senior living provider in New England, today announced that Nick Barash of Andover, Mass., executive director of Benchmark at Rye , a Mind & Memory Care community, has received the Benchmark 2023 President's Award, which is the Waltham-based company's highest honor for associates in a senior leadership role.
  • -Tom Grape, founder, chairman and CEO, Benchmark Senior Living
    At the company's 21st Annual Awards Gala held on March 7, 2024, Barash was selected for exhibiting outstanding operational leadership at his previous community, Benchmark Senior Living at Haverhill Crossings and at his present community, Benchmark at Rye, a memory care assisted living community.
  • Barash was hailed for frequently going above and beyond for residents, their families and associates, which has resulted in increased satisfaction across the community.
  • "The compassion and care our associates exhibit daily is truly inspiring," said Tom Grape, founder, chairman and CEO of Benchmark.

Salary.com Releases New Research on Compensation Challenges Facing Businesses Today

Retrieved on: 
Tuesday, April 9, 2024
Emergent, Artificial intelligence, Kenexa, HR, Research, Classic, Diversity, Sales

--Remote work: solving the conflict between workforce realities and old-school needs

Key Points: 
  • The company released the initial results of its research into compensation pitfalls.
  • Our research team has crafted a roadmap to guide compensation and HR professionals through this maze of challenges.”
    Salary.com® has a free infographic for companies to download .
  • That graphic starts with Classic Pitfalls: the tough challenges that compensation departments have always wrestled with.
  • The infographic also includes a series of Emergent Pitfalls: challenges that have only risen to prominence in recent years.

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, Half-life, Patient, Tumor microenvironment, Observation, Interleukin 18, AACR, Neoplasm, Cancer, Cytokine, Immune system, IL-12, Vaccine

WALTHAM, Mass and DUBLIN, Ireland, April 09, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today shared poster presentations with pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at the American Association for Cancer Research (AACR) annual meeting taking place April 5-10 in San Diego, California. This is the first time Mural has shared findings from either program. The details for the presentations are as follows, and both posters are available at https://www.muraloncology.com/publications/.

Key Points: 
  • Mural’s protein engineering approach is twofold: first, it introduces mutations to IL-18 that are designed to minimally impact the structure while eliminating binding to IL-18BP.
  • The optimal balance of potency and pharmacokinetic enhancement is still being determined to nominate a lead IL-18 development candidate.
  • We show that resistance to IL-18BP combined with the drug’s extended half-life leads to a durable immunological effect in preclinical models.
  • “We believe that by self-assembling the split IL-12 subunits within the tumor microenvironments, we can circumvent native IL-12’s severe toxicities without compromising its efficacy.

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Retrieved on: 
Tuesday, April 9, 2024
Brain, Disease, CNS, Mouse, Neoplasm, IND, AACR, HER2, Poster, Annual general meeting, Cogent, Pharmaceutical industry

and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program.

Key Points: 
  • and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program.
  • The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taking place in San Diego, California.
  • “These data further demonstrate Cogent’s capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet medical need.
  • Cogent is developing a potential best-in-class EGFR-sparing, brain-penetrant ErbB2 inhibitor that includes potent coverage of key mutations (YVMA, S310F, V842I, L755S) inadequately addressed by currently approved therapies.